Literature DB >> 15558784

Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders.

Robert McGlynn1, Kostantin Dobrenis, Steven U Walkley.   

Abstract

The mucopolysaccharidoses (MPSs) are a complex family of lysosomal storage disorders characterized by failure to degrade heparan sulfate (HS) and/or other types of glycosaminoglycans (GAGs) secondary to the absence of specific lysosomal enzymes. An accompanying storage of glycosphingolipids (GSLs), most notably GM2 and GM3 gangliosides, has also been documented to occur in many types of MPS disease and is believed to be caused by secondary inhibition of GSL-degradative enzymes by intracellular GAG accumulation. We have documented the presence of secondary ganglioside accumulation in mouse models of several MPS disorders (types I, IIIA, IIIB, and VII) and report that this storage is accompanied by sequestration of free cholesterol in a manner similar to that observed in primary gangliosidoses. Using confocal microscopy, we evaluated the cellular distribution of cholesterol, GM2 and GM3 gangliosides, and HS in brains of mice with MPS IIIA disease. Unexpectedly, we found that although both gangliosides often accumulated in the same neurons, they were consistently located in separate populations of cytoplasmic vesicles. Additionally, GM3 ganglioside only partially co-localized with the primary storage material (HS), and cholesterol likewise only partially co-localized with the GM2 and GM3 gangliosides. These findings raise significant questions about the mechanism(s) responsible for secondary accumulation of storage materials in MPS disease. Furthermore, given that GSLs and cholesterol are constituents of membrane rafts believed critical in signal transduction events in neurons, their co-sequestration in individual neurons suggests the presence of defects in the composition, trafficking, and/or recycling of raft components and thus possible new mechanisms to explain neuronal dysfunction in MPS disorders. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15558784     DOI: 10.1002/cne.20355

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  88 in total

1.  Storage vesicles in neurons are related to Golgi complex alterations in mucopolysaccharidosis IIIB.

Authors:  Sandrine Vitry; Julie Bruyère; Michaël Hocquemiller; Stéphanie Bigou; Jérôme Ausseil; Marie-Anne Colle; Marie-Christine Prévost; Jean Michel Heard
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

2.  Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.

Authors:  Haiyan Fu; Aaron S Meadows; Tierra Ware; Robert P Mohney; Douglas M McCarty
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

3.  N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV.

Authors:  Lauren C Boudewyn; Jakub Sikora; Ladislav Kuchar; Jana Ledvinova; Yulia Grishchuk; Shirley L Wang; Kostantin Dobrenis; Steven U Walkley
Journal:  Neurobiol Dis       Date:  2017-06-10       Impact factor: 5.996

Review 4.  Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity.

Authors:  Louise D Archer; Kia J Langford-Smith; Brian W Bigger; James E Fildes
Journal:  J Inherit Metab Dis       Date:  2013-05-08       Impact factor: 4.982

5.  Selective exo-enzymatic labeling of N-glycans on the surface of living cells by recombinant ST6Gal I.

Authors:  Ngalle Eric Mbua; Xiuru Li; Heather R Flanagan-Steet; Lu Meng; Kazuhiro Aoki; Kelley W Moremen; Margreet A Wolfert; Richard Steet; Geert-Jan Boons
Journal:  Angew Chem Int Ed Engl       Date:  2013-10-15       Impact factor: 15.336

6.  Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I.

Authors:  Christian Hinderer; Peter Bell; Brittney L Gurda; Qiang Wang; Jean-Pierre Louboutin; Yanqing Zhu; Jessica Bagel; Patricia O'Donnell; Tracey Sikora; Therese Ruane; Ping Wang; Mark E Haskins; James M Wilson
Journal:  Mol Ther       Date:  2014-07-16       Impact factor: 11.454

7.  Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model.

Authors:  Siamak Jabbarzadeh-Tabrizi; Michel Boutin; Taniqua S Day; Mouna Taroua; Raphael Schiffmann; Christiane Auray-Blais; Jin-Song Shen
Journal:  J Lipid Res       Date:  2020-08-31       Impact factor: 5.922

8.  Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response.

Authors:  Smruti Killedar; Julianne Dirosario; Erin Divers; Phillip G Popovich; Douglas M McCarty; Haiyan Fu
Journal:  J Neuroinflammation       Date:  2010-07-16       Impact factor: 8.322

9.  Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease.

Authors:  Marcelina Malinowska; Fiona L Wilkinson; Kia J Langford-Smith; Alex Langford-Smith; Jillian R Brown; Brett E Crawford; Marie T Vanier; Grzegorz Grynkiewicz; Rob F Wynn; J Ed Wraith; Grzegorz Wegrzyn; Brian W Bigger
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

10.  Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.

Authors:  Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.